Cargando…

Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson’s Disease Modifier Genes

Antipsychotic-induced movement disorders are major side effects of antipsychotic drugs among schizophrenia patients, and include antipsychotic-induced parkinsonism (AIP) and tardive dyskinesia (TD). Substantial pharmacogenetic work has been done in this field, and several susceptibility variants hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenbaum, Lior, Lerer, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335175/ https://www.ncbi.nlm.nih.gov/pubmed/25750634 http://dx.doi.org/10.3389/fneur.2015.00027

Ejemplares similares

Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation
por: Lerer, Bernard, et al.
Publicado: (2006)

Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease
por: Greenbaum, Lior, et al.
Publicado: (2013)

Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson’s Disease
por: Lasbleiz, Christelle, et al.
Publicado: (2019)

Pharmacogenetics and outcome with antipsychotic drugs
por: Pouget, Jennie G., et al.
Publicado: (2014)

Pharmacogenetics of antipsychotic-induced side effects
por: Lencz, Todd, et al.
Publicado: (2009)

The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
por: Reynolds, Gavin P
Publicado: (2012)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

A commentary on “Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders”
por: Salem, Amir, et al.
Publicado: (2015)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

Response to: A Commentary on “Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders”
por: Potvin, Stéphane, et al.
Publicado: (2015)

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
por: Eum, Seenae, et al.
Publicado: (2016)

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2018)

A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
por: Arranz, Maria J., et al.
Publicado: (2019)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders
por: Vasiliu, Octavian
Publicado: (2023)

Experimental treatment of antipsychotic-induced movement disorders
por: Shireen, Erum
Publicado: (2016)

Editorial: Insights into Parkinson's disease and aging related movement disorders
por: Petersen, Robert B., et al.
Publicado: (2023)

On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease
por: Troncoso-Escudero, Paulina, et al.
Publicado: (2020)

Minor hallucinations in Parkinson’s disease with probable rapid eye movement sleep behavior disorder
por: Jiang, Yinyin, et al.
Publicado: (2023)

Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2019)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Antipsychotic Effects on Cortical Morphology in Schizophrenia and Bipolar Disorders
por: Feng, Ruiqi, et al.
Publicado: (2020)

Association of the Type 2 Diabetes Mellitus Susceptibility Gene, TCF7L2, with Schizophrenia in an Arab-Israeli Family Sample
por: Alkelai, Anna, et al.
Publicado: (2012)

Editorial: Sound, Music, and Movement in Parkinson’s Disease
por: Bieńkiewicz, Marta M. N., et al.
Publicado: (2016)

Alterations of Brain Structural Network in Parkinson’s Disease With and Without Rapid Eye Movement Sleep Behavior Disorder
por: Guo, Tao, et al.
Publicado: (2018)

Zebrafish as an Animal Model for Drug Discovery in Parkinson’s Disease and Other Movement Disorders: A Systematic Review
por: Vaz, Rita L., et al.
Publicado: (2018)

Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease
por: Si, Xiao-li, et al.
Publicado: (2020)

Sleep and Autonomic Manifestations in Parkinson’s Disease Complicated With Probable Rapid Eye Movement Sleep Behavior Disorder
por: Fujita, Hiroaki, et al.
Publicado: (2022)

SNCA rs3910105 Is Associated With Development of Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease
por: Yang, Nan-nan, et al.
Publicado: (2022)

Instantaneous movement-unrelated midbrain activity modifies ongoing eye movements
por: Buonocore, Antimo, et al.
Publicado: (2021)

Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians
por: Foster, Adriana, et al.
Publicado: (2007)

Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
por: Reynolds, Gavin P.
Publicado: (2012)

Pharmacogenetic markers to predict safety of antipsychotics in adolescents experiencing acute psychotic episodes
por: Ivashchenko, D., et al.
Publicado: (2022)

Glossary: Definitions Useful in Understanding Pharmacogenetics
por: Farkas, D.
Publicado: (2008)

Eye Movements in Parkinson’s Disease and Inherited Parkinsonian Syndromes
por: Pretegiani, Elena, et al.
Publicado: (2017)

Editorial: Bringing together data- and knowledge-driven solutions for a better understanding and effective diagnostics of neurological disorders
por: Kaplun, Dmitrii, et al.
Publicado: (2023)

Blood Gene Expression Profile Predicts Response to Antipsychotics
por: Sainz, Jesus, et al.
Publicado: (2018)

Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management
por: Ward, Kristen M., et al.
Publicado: (2018)

The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson’s disease
por: Tao, Mingzhu, et al.
Publicado: (2022)

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents
por: Kannarkat, George T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c55j3gnosg83pb1gcq2jlhikjc